Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
FIVE PRIME THERAPEUTICS, INC. (FPRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/18/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of FRTA, AEGN, FPRX, and MIK Buyouts |
| 03/08/2021 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Investigates SVBI, FPRX, MIK, JCS; Shareholders Are Encouraged to Contact the Firm |
| 03/04/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Five Prime Therapeutics, Inc. Buyout |
| 03/04/2021 |
GN
| FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm |
| 11/10/2020 |
GN
| Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer |
| 10/10/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek — Fundamental Analysis, Key Performance Indications |
| 02/15/2018 |
GN
| New Research Coverage Highlights Trevena, Five Prime Therapeutics, Endocyte, FireEye, CSRA, and Orchid Island Capital — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 02/13/2018 |
GN
| Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27 |
| 02/08/2018 |
GN
| Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference |
| 01/29/2018 |
GN
| Five Prime Therapeutics Announces Closing of Upsized Public Offering |
| 01/25/2018 |
GN
| Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone |
| 01/23/2018 |
GN
| Five Prime Announces Proposed Public Offering of Common Stock |
| 01/08/2018 |
GN
| Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time |
| 01/03/2018 |
GN
| Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150 |
| 01/03/2018 |
GN
| Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference |
| 01/02/2018 |
GN
| Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer |
| 12/19/2017 |
GN
| Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration |
| 12/04/2017 |
GN
| Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference |
| 11/10/2017 |
GN
| Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting |
| 11/07/2017 |
GN
| Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting |
| 11/06/2017 |
GN
| Five Prime Announces Third Quarter 2017 Results and Provides Business Update |
| 10/30/2017 |
GN
| Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 |
| 10/23/2017 |
GN
| Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 |
| 10/18/2017 |
GN
| Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| 10/11/2017 |
GN
| Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting |
| 09/21/2017 |
GN
| Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology |
| 09/10/2017 |
GN
| Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress |
| 09/10/2017 |
GN
| Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress |
| 09/01/2017 |
GN
| Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress |
| 08/29/2017 |
GN
| Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress |
| 08/17/2017 |
GN
| Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research |
| 07/17/2017 |
GN
| Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development |
| 06/21/2017 |
GN
| Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 |
| 06/05/2017 |
GN
| Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference |
|
|
|